Medtronic plc MDT used its first-quarter fiscal 2027 earnings call to emphasize that growth is broadening across major franchises while newer platforms gain scale. Management also raised its full-year outlook and defended continued investment in robotics, ablation and other higher-growth areas.
Adjusted earnings of $1.45 per share topped the Zacks Consensus Estimate of $1.39. Revenues of $9.76 billion also exceeded the consensus estimate of $9.47 billion by 3.00%.
MDT Raises FY27 Outlook and Sets Q2 Bar
Executive vice president and CFO Thierry Pieton raised fiscal 2027 organic revenue growth guidance to 7.25-7.75% from 6.75-7.25%.
Pieton also increased adjusted earnings guidance to $5.94-$6.00 from $5.90-$6.00. For the second quarter, management expects roughly 6% organic revenue growth and adjusted earnings of $1.32-$1.34 per share.
Pieton said foreign exchange is expected to be a $50-$150 million full-year headwind, including a $25-$75 million second-quarter headwind.
Medtronic Sees Broader Growth Beyond CAS
Chairman and CEO Geoff Martha stressed that the quarter was not driven by one franchise. Cardiac Rhythm Management grew 15%, Cranial & Spinal Technologies rose 13%, and Surgical advanced 9%.
Martha also highlighted Cardiac Ablation Solutions, which grew 88% worldwide. Sphere-9 gained 9 points of U.S. share, while the U.S. Affera installed base increased more than 35% sequentially.
Pieton said CAS is expected to grow at 2.5 times the market rate for fiscal 2027 and more than three times the market rate in the second quarter as comparisons get tougher.
MDT Defends Hugo While Expanding Robotics
A Wells Fargo analyst asked whether Medtronic's $700 million Cornerstone Robotics investment reflected reduced confidence in Hugo. Chairman and CEO Geoff Martha rejected that interpretation and said the deal expands global access and customer choice.
Martha said Hugo remains the company's U.S. robotics platform, with more than 50,000 completed procedures expected by fiscal year-end. Medtronic is also expanding indications, instruments and digital capabilities around the system.
Executive Vice President and CFO Thierry Pieton said the Cornerstone deal should have minimal fiscal 2027 financial impact beyond foregone interest. He expects the distribution agreement to begin contributing to volume and margins in fiscal 2028.
Medtronic Balances Reinvestment With Margin Gains
Executive Vice President and CFO Thierry Pieton said adjusted gross margin was 65.2%, up 10 basis points, as pricing and cost reductions offset unfavorable mix.
Adjusted operating margin rose 10 basis points to 23.7%. Pieton continues to expect about 50 basis points of full-year operating margin expansion and approximately 10% operating profit growth.
A JPMorgan analyst pressed management on reinvestment and tariffs. Pieton said Medtronic is reinvesting only part of the revenue upside, while first-quarter tariff refunds nearly offset tariff costs. The full-year outlook does not assume future refunds.
MDT Keeps Capital Focus on High-Growth Tuck-Ins
A Mizuho analyst asked how capital allocation could change after the planned Diabetes separation. Chairman and CEO Geoff Martha said Medtronic's emphasis remains on tuck-in acquisitions, venture investments and structured deals rather than scale transactions.
Executive Vice President and CFO Thierry Pieton said recent acquisitions are expected to contribute more than $150 million of inorganic revenue in fiscal 2027. He also said deconsolidating Diabetes would raise gross margin by about 50 basis points and operating margin by about 100 basis points.
Pieton said Medtronic has no specific buyback plan, while retaining flexibility for tactical repurchases under the right conditions.
Medtronic Keeps Growth and Efficiency in Tandem
Chairman and CEO Geoff Martha framed the quarter as evidence that Medtronic's strategy is translating into broader commercial execution, with established franchises and newer growth platforms contributing together.
Executive Vice President and CFO Thierry Pieton kept the focus on pricing, cost reductions, portfolio simplification and targeted investment, aiming to pair stronger revenue growth with operating leverage.
MDT's Zacks Signals Remain Mixed
MDT carries a Zacks Rank #3 (Hold), along with a Value Score of B, Growth Score of C, Momentum Score of C and VGM Score of B. Under the Zacks framework, the B grades are more favorable than the C grades, while a Zacks Rank #3 indicates a neutral standing versus the top-ranked stocks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Style Scores are designed to complement the Zacks Rank, with A and B grades representing stronger characteristics within each style. The Zacks Rank can change as earnings estimates are revised following the just-reported results.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
